Myriad Genetics Inc (NASDAQ:MYGN)

24.49
Delayed Data
As of May 24
 +0.35 / +1.45%
Today’s Change
23.93
Today|||52-Week Range
50.44
-15.76%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$1.9B

Company Description

Myriad Genetics, Inc. engages in the discovery, development, and marketing of transformative molecular diagnostic test. It operates through Diagnostics and Other segments. The Diagnostics segment engages in the provision of testing and collaborative development of testing that is designed to asses a risk of developing a disease later in life of an individual. The Other segmeng provides products and services to the pharmaceutical, biotechnology and medical research industries, research and development, and clinical services for patients, and includes corporate services such as finance, human resources, legal and information technology. The company was founded by Walter A. Gilbert, Mark H. Skolnick and Peter D. Meldrum in May 1991 and is headquartered in Salt Lake, UT.

Contact Information

Myriad Genetics, Inc.
320 Wakara Way
Salt Lake City Utah 84108
P:(801) 584-3600
Investor Relations:
(801) 584-1143

Employees

Shareholders

Other institutional55.46%
Mutual fund holders54.72%
Individual stakeholders4.60%

Top Executives

Mark C. CaponePresident, Chief Executive Officer & Director
Gary A. KingExecutive Vice President-International Operations
R. Bryan RiggsbeeCFO, Treasurer, Principal Accounting Officer & EVP
Robert Gardner HarrisonChief Information Officer
Jerry S. LanchburyChief Scientific Officer